Paxmedica, inc. announces second quarter 2023 financial results and business update

Tarrytown, ny, aug. 09, 2023 (globe newswire) -- via newmediawire – paxmedica, inc. (nasdaq: pxmd), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“apt”) for the treatment of disorders with intractable neurologic symptoms, today provided a business update and reported financial results for the second quarter 2023, ended june 30, 2023.
PXMD Ratings Summary
PXMD Quant Ranking